Autolus Therapeutics plc - Special Call Transcript
Good day, and welcome to the Autolus Therapeutics ESMO Investor Conference Call. (Operator Instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Lucinda Crabtree, Vice President, Investor Relations. Please go ahead.
Thank you, Cole. Good morning or good afternoon, everyone, and thank you for taking part in today's call on the ESMO AUTO3 Phase I/II data update. I'm Lucinda Crabtree, Vice President of Investor Relations. With me today are Dr. Christian Itin, our Chairman and Chief Executive Officer; Dr. Robert Chen, our AUTO3 and lymphoma program lead; Dr. Nushmia Khokhar, our lead -- Head of Clinical Development; Brent Rice, our Chief Commercial Officer; and Andrew Oakley, our Chief Financial Officer.
Before we begin, I would like to remind you that during today's call, our discussion today will contain forward-looking statements. All statements other than statements of historical facts on this call are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |